Hyperglycemia in pregnancy and beyond

Live Webinar

Hyperglycemia in pregnancy and beyond

E-learning Modules

Launch: 18 October 2024


The nature of pregnant women has changed in recent years: women are more likely to give birth at an older maternal age, and more women are likely to be obese when they become pregnant. The number of women with pre-existing type 2 diabetes who become pregnant are also associated with an increased prevalence of gestational diabetes mellitus, which is recognized as a global health concern [Vounzoulaki, 2020].

Perinatal morbidity and mortality in pregnancies complicated by diabetes mellitus is much higher than in the general obstetric population [Goodman, 2023]. In addition, a diagnosis of gestational diabetes mellitus increases the risk of cardiometabolic diseases (including type 2 diabetes) for both mother and child in later life [IDF Atlas, 2021; Alba-Linares, 2023]. Therefore, it is vital that hyperglycemia is screened for in every woman in pregnancy, through oral glucose tolerance testing and individual consideration of risk factors for the condition [IDF Atlas, 2021].

In the developing world and/or marginalized community-based populations, optimum screening strategies are unclear [Prüst, 2022; Ramezani Tehrani, 2023]. Consequently, there are unmet needs in real-world clinical care relating to awareness and implementation of guidelines for gestational diabetes screening and management [Vounzoulaki, 2020]. The follow-up screening of women with a history of gestational diabetes is necessary to ensure timely identification of pre-diabetes and type 2 diabetes in these high-risk individuals [Björk Javanshiri, 2023].

Learning Objectives

After attended this webinar, participants will be able to:

Target Audience

Clinicians involved in endocrinology, particularly diabetes, pre-diabetes; fertility and pregnancy management, obesity management and general practice; some content of interest to midwives and nurses involved in pre-natal and post-natal care; some content of interest to vascular specialists and podiatrists.


English with simultaneous translation into Spanish and Chinese


Raffaella Buzzetti

Raffaella Buzzetti

Ernesto Maddaloni

Ernesto Maddaloni

Sapienza University of Rome
Rome, Italy
Nemencio A. Nicodemus Jr.

Nemencio A. Nicodemus Jr.

College of Medicine
Department of Biochemistry & Molecular Biology
University of the Philippines
Philippine General Hospital
Department of Medicine

Sign up for the module

Final Programme

Download Final Programme

· Ernesto Maddaloni ·

Dr Ernesto Maddaloni, is currently Assistant Professor of Endocrinology and Diabetes at Sapienza University of Rome, Italy. He gained his MD, clinical specialty in Endocrinology and Diabetes and PhD in “Integrated Biomedical Sciences and Bioethics” at Campus Bio-Medico University of Rome. He has joined the Vascular Cell Biology Section of the Joslin Diabetes Center (Harvard Medical School) for a Post-Doctoral Research Fellowship in 2014 and the Diabetes Trial Unit of the University of Oxford in 2017 as a mentee of the European Foundation for the Study of Diabetes (EFSD) Future Leaders Mentorship Program, to actively pursuing his studies on clinical diabetes, cardiovascular outcomes and novel diabetes complications. His research interests focus on the study of adults with autoimmune diabetes and the interplay between vascular complications, bone health and autoimmunity. After the Sars-CoV2 infection outbreak, he has contributed also with original articles evaluating the strict relationship between diabetes and related comorbidities with Covid-19. Dr Maddaloni has been a study investigator and coordinator for several national and international clinical trials and has published as lead author in several top-ranked peer-reviewed international medical journals.

His scientific achievements have been recognized with several awards, including the 2015 Albert Renold Fellowship from the European Foundation for the Study of Diabetes, the 2017 (under 32) and 2021 (under 35) Young Investigator Awards from the Italian Society of Endocrinology (SIE), the 2017 Early Investigator Award from the Endocrine Society (USA) and the 2020 Young (under 35) Investigator Award from the Italian Society of Diabetes (SID).

· Nemencio A. Nicodemus Jr. ·

Currently serving as Professor of the Department of Biochemistry and Molecular Biology at the University of the Philippines College of Medicine, and a Clinical Professor at the Division of Endocrinology, Diabetes and Metabolism of the Department of Medicine at the Philippine General Hospital, Dr Nemencio Nicodemus Jr. is also Vice Chair for Postgraduate Training and the departmental training officer. Nationally, Prof. Nicodemus is the Treasurer of the Philippine College of Physicians, President of the Philippine Association for the Study of Overweight and Obesity (PASOO) and a past President of the Philippine Thyroid Association and the Philippine Society of Endocrinology, Diabetes and Metabolism. An active and engaging lecturer, Dr Nicodemus has been invited to several regional and international conferences, including the International Society of Endocrinology, International Diabetes Federation and ASEAN Federation of Endocrine Societies as a resource speaker. Prof. Nicodemus has published several articles and book chapters on diabetes, thyroid and obesity. He is a member of the technical committee who oversee clinical practice guidelines on diabetes in pregnancy and thyroid disorders in pregnancy, including guidelines on recurrent pregnancy loss in the Philippines. 

· Martin O. Savage ·

Martin Savage is Emeritus Professor of Paediatric Endocrinology at William Harvey Research Institute, Barts and the London School of Medicine & Dentistry, Queen Mary, University of London. He was head of the Paediatric Endocrine Unit at Barts and the London School of Medicine from 1982 to 2007. He has interests in growth disorders, specifically those with abnormalities in the GH-IGF-1 axis and in phenotype-genotype relationships of GH-IGF-1 axis defects, notably GH resistance. He published the first human case of an IGF-1 gene defect in the New England Journal of Medicine in 1996.  His other interests are Cushing’s syndrome and growth in chronic inflammatory diseases. He was General Secretary of the European Society for Paediatric Endocrinology (ESPE) from 1997 to 2004. He has lectured in 61 countries and has published 472 original articles, reviews, textbook chapters and books. In 2007, he was awarded the ESPE Andrea Prader Prize for contributions to paediatric endocrinology and in 2018 he received a Visionary Award from the American Human Growth Foundation. In 2022, he received a Research Excellence Award from the Dr Sulaiman Al Habib Medical Journal in Riyadh, and the British Society of Paediatric Endocrinology & Diabetes James M. Tanner Lifetime Achievement Award. He continues to lecture nationally and internationally.